Invivyd (IVVD) Set to Release Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $15.04 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. The business had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. On average, analysts expect Invivyd to post ($0.51) EPS for the current fiscal year and ($0.43) EPS for the next fiscal year.

Invivyd Trading Down 0.3%

IVVD opened at $0.58 on Tuesday. The business has a 50 day moving average of $0.78 and a 200-day moving average of $1.17. The stock has a market capitalization of $170.96 million, a price-to-earnings ratio of -1.76 and a beta of 0.95. Invivyd has a 1-year low of $0.53 and a 1-year high of $3.07.

Analyst Upgrades and Downgrades

IVVD has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Invivyd in a research note on Thursday, August 27th. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Monday, September 14th. Weiss Ratings upgraded shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Finally, HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Invivyd presently has an average rating of “Hold” and an average price target of $10.00.

Insider Buying and Selling at Invivyd

In other news, insider Jill Andersen sold 30,706 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $25,793.04. Following the sale, the insider directly owned 283,774 shares in the company, valued at approximately $238,370.16. The trade was a 9.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 228,024 shares of company stock worth $176,540. 12.25% of the stock is currently owned by company insiders.

Invivyd Company Profile

Invivyd, Inc is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve.

Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.